Relmada Therapeutics Reports $19.05 Million Net Loss and Significant Cash Position Growth

Relmada Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded a net loss of approximately $19.05 million, or $0.22 per share, compared to a net loss of $17.56 million, or $0.58 per share, for the same period in 2025. Total operating expenses increased slightly to $19.46 million from $18.22 million year-over-year, driven primarily by a rise in general and administrative expenses, which surged to $11.37 million from $6.27 million. In contrast, research and development expenses decreased to $8.09 million from $11.95 million, reflecting a strategic shift in the company's focus and the winding down of certain projects.

The company experienced a substantial increase in its cash position, with cash and cash equivalents rising to $9.78 million from $3.50 million at the end of 2025. Additionally, short-term investments saw a significant increase, climbing to $224.19 million from $89.51 million. This growth in liquidity was bolstered by a successful private placement in March 2026, which generated approximately $150 million in net proceeds from the sale of common stock and pre-funded warrants. This influx of capital is expected to support ongoing clinical trials and operational expenses for at least the next 12 months.

Strategically, Relmada has made notable advancements in its product pipeline. The company is currently focused on two primary candidates: NDV-01, a controlled-release formulation for treating non-muscle invasive bladder cancer (NMIBC), and sepranolone, a neurosteroid aimed at treating Prader-Willi Syndrome and other conditions. NDV-01 is in a Phase 2 clinical trial in Israel, with plans to initiate Phase 3 trials for two indications by mid-2026. The acquisition of sepranolone from Asarina Pharma in early 2025 has also positioned the company to explore additional therapeutic avenues.

Operationally, Relmada's employee headcount has increased, contributing to higher general and administrative costs. The company is actively expanding its clinical development capabilities, which is reflected in the increased compensation expenses. As of March 31, 2026, the company had approximately 15 million stock options and warrants outstanding, indicating a robust engagement with its employee base. The company’s strategic focus on enhancing its product pipeline and operational capabilities is expected to drive future growth, although it remains subject to the inherent risks of clinical development and regulatory approval processes.

Looking ahead, Relmada anticipates several key milestones, including the filing of an Investigational New Drug (IND) application for NDV-01 with the FDA and the initiation of Phase 2b studies for sepranolone. The company is optimistic about its prospects, although it acknowledges the ongoing need for additional financing to support its clinical trials and operational needs beyond the next year.